Winnie Hua

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

Philippe Moreau, Cyrille Hulin, Aurore Perrot et al. · The Lancet Oncology · 2024 · 112 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study

Leslie R. Harrold, Heather J. Litman, Seán Connolly et al. · The Journal of Rheumatology · 2017 · 55 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +15

Characterization of Patients With Axial Spondyloarthritis by Enthesitis Presence: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

Philip J. Mease, Mei Liu, Sabrina Rebello et al. · ACR Open Rheumatology · 2020 · 38 citations · Full text

Medicine, Internal Medicine, Dermatopathology +12

Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry

Leslie R. Harrold, Heather J. Litman, Seán Connolly et al. · Rheumatology and Therapy · 2019 · 27 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +15

A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice?

Leslie R. Harrold, Heather J. Litman, Seán Connolly et al. · Clinical Rheumatology · 2017 · 23 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17